Erin Digennaro

About Erin Digennaro

Strategic commercial leader with 15+ years of success driving accelerated revenue growth and market expansion across multi-million-dollar portfolios. Recognized for building inclusive, high-retention teams that consistently outperform national benchmarks while executing sophisticated pull-through strategies across IDNs, health systems, and community settings. Known for translating complex clinical and market data into clear priorities, aligning cross-functional PODs, and maximizing ROI through disciplined resource allocation and customer-centric execution. Well-suited for senior leadership roles within highly matrixed, enterprise-level organizations.Expertise: Commercial Leadership | Cardiorenal | CVR | Rare Disease| Health Systems| Team Development | Revenue GrowthEnterprise & IDN Strategy | Cross-Functional POD Leadership | Market Share Expansion | Data-Driven Decisions Coaching & Mentorship | Inclusive Culture | Team Retention | Strategic Account Management | KOL DevelopmentPull-Through Strategy | Market Access Collaboration | Medical Affairs Partnership | Business Planning

Experience

1. Area General Manager

   Bayer

   Jan 2024 — Present · Los Angeles, CA, US

   Leading a high-performing Cardiorenal and Rare Disease business unit across the Los Angeles area, overseeing a team of 13 sales representatives and a Regional Associate Director while driving enterprise-level growth within complex health systems and IDNs.• Built and sustained one of the top-performing teams nationally, ranking Top 10% or better every year since promotion, including #8 nationally YTD 2025 and #4 nationally in 2022 and 2023.• Fostered an inclusive, high-engagement culture with near-zero voluntary turnover, retaining top talent while supporting internal promotions and long-term career growth.• Drove 60% Kerendia revenue growth to nearly $30M, representing approximately 20% of total West Area squad revenue and the largest net sales contribution in the region.• Grew Adempas revenue by 30% to $15M while maintaining 85% overall profitability, demonstrating strong commercial discipline and return on investment.• Delivered best-in-nation execution metrics, including highest total paid nationally (78%) and 81% paid rate for P1 targets, demonstrating disciplined investment and ROI optimization.• Produced above-national performance across all key customer segments, achieving reach and NBRx rates well above benchmarks (e.g, P1 Cardiologists: 80% reach / 34% NBRx vs. 13% national).• Partnered closely with RADs, MSLs, Market Access, and representatives in POD structures to design and execute pull-through strategies that accelerated adoption across offices, systems, and IDNs.

Education

• UC Santa Barbara

  BA, Economics

Skills

• Strategy
• Sales